|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The interaction between TeNWs and intracellular H<sub>2</sub>O<sub>2</sub> produces toxic TeO<sub>6</sub><sup>6-</sup> molecules greatly enhanced ROS generation, and the reaction product, verified as TeO<sub>6</sub><sup>6-</sup>, would react with glutathione (GSH) and thus decrease intracellular GSH levels, which greatly increases ROS levels in the tumor.
|
31588274 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical staining for ROS1 was positive in the tumor cytoplasm.
|
30350109 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This synthesized semiconductor-metal heterojunction served as a superior photodynamic agent, showing prominent cancer cell-killing and tumor growth-suppressing effects in the presence of a 670 nm light and g-C<sub>3</sub>N<sub>4</sub>-AuNP composites, and its excellent ROS generation property was also validated by further bactericidal experiment.
|
30816032 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It can inhibit tumor cell growth in ALK- and ROS1-overexpressing tumor cells.
|
30657349 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients were assessed for clinical features and tumor genomic characteristics such as ROS1 and NTRK1 rearrangements, KIT, PDGFRA, and KDR amplification, and RB1 deletion using multicolor fluorescence in situ hybridization.
|
30840759 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A NGS assay showed that the tumor had a novel ROS1-ADGRG6 rearrangement generated by the fusion of exons of 1-33 of ROS1 on chr6: q22.1 to exons of 2-26 of ADGRG6 on chr6: q24.2.
|
31382924 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Its effects on apoptosis, reactive oxygen species (ROS) generation, cell invasion, cell cycle arrest and its effects on tumor volume and weight were also evaluated in the current study.
|
30941982 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Copy number profiling revealed chromosome 6q22 microdeletions corresponding to the GOPC-ROS1 fusion in all 3 cases and methylation profiling showed that the tumors did not cluster together as a single entity or within known methylation classes by t-Distributed Stochastic Neighbor Embedding.
|
31626289 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we employed a template method to develop the core-shell gold nanocage@manganese dioxide (AuNC@MnO<sub>2</sub>, AM) nanoparticles as tumor microenvironment responsive oxygen producers and near-infrared (NIR)-triggered reactive oxygen species (ROS) generators for oxygen-boosted immunogenic PDT against mTNBC.
|
29890364 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings demonstrate that activation of STAT3 and Bcl-2 and reduction of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors.
|
29855616 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, decreasing the intracellular glutathione (GSH) level through the -S-S-/GSH redox chemistry increases the ROS generation level both in vitro and in vivo, facilitating cytotoxic T lymphocyte (CTL) proliferation and reducing tumour growth in an aggressive B16-OVA melanoma tumour model.
|
29803106 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Entrectinib (RXDX-101) is a pan-ALK, TRKA, TRKB, TRKC, and ROS1 inhibitor with activity against tumors with <i>ALK</i>, <i>NTRK1</i>, <i>NTRK2</i>, <i>NTRK3</i>, and <i>ROS1</i> alterations in Phase I clinical trials in adults.
|
30425456 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the current study, we aimed to investigate the frequency and clinicopathologic features associated with ROS1 gene fusion and ROS1 protein expression in patients with ovarian serous carcinoma or serous borderline tumors.
|
30249502 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The rates of ROS1 rearrangement differed by tumor histologic subtype in NSCLC.
|
29874982 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ROS1-rearranged NSCLCs were significantly more likely to be found in younger patients and at an advanced stage; they showed cribriform features, extracellular mucus and psammoma bodies, whereas ROS1-discordant cases were found in older patients at a relatively early tumour-node-metastasis (TNM) stage and showed a lepidic growth pattern (all P < 0.001).
|
29464758 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report.
|
30593165 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oral monotherapy with a brain-permeable ROS1 inhibitor, lorlatinib, significantly prolonged survival in an intracranially xenografted tumor model generated from a ROS1 fusion-positive glioblastoma cell line.
|
30171048 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We used the FlexISH ALK/ROS1 DistinguISH Probe (Zytovision, Bremerhaven, Germany) to analyze a set of 28 formalin-fixed paraffin-embedded NSCLC tumor samples enriched in tumors with ALK- and ROS1-rearranged status.
|
29801706 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Complex 1 exhibited dual effects in the inhibition of tumor cell proliferation of SMMC7721 cells, causing nuclear DNA damage and mitochondrial dysfunction involving simultaneous reactive oxygen species (ROS) generation and Ca<sup>2+</sup> increase.
|
29990748 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the last decade it became evident that many lung adenocarcinomas (ADC) harbor key genetic alterations such as KRAS, EGFR or BRAF mutations as well as rearrangements of ROS1 or ALK that drive these tumors.
|
29487011 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multifaceted mechanisms of action underlying ROS generation in tumor and nontumor cells versus As<sup>III</sup> and DMA<sup>V</sup> exposure are thus involved.
|
29498595 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the efficacy of ROS generation for tumour damage is highly dependent on the uptake of the PS in tumour cells.
|
30322132 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the efficacy of ROS generation for tumour destruction is highly dependent on the accumulation of the PS in tumour cells.
|
29588217 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The repolarization of tumor-associated macrophages not only prompted the ROS generation but also induced the innate immunity (e.g., antitumor cytokine release).
|
30096402 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, a NIR light was used to effectively increase the local temperature of tumor in virtue of the superior photothermal effects of MSP, which enabled us to accelerate the ROS generation and achieved an enhanced ROS yield.
|
29337533 |
2018 |